Pneumonia News and Research

Latest Pneumonia News and Research

University of Alberta medical research supports the 'obesity paradox'

Medical researchers at the University of Alberta studied the records of nearly 1000 patients who were admitted to hospital with pneumonia and noted those who were obese were more apt to survive compared to those who were of normal weight.

6 Nov 2012

Sapacitabine tolerated, efficacious in elderly leukemia patients

The nucleoside analog sapacitabine appears to be “active and tolerable” in elderly patients with acute myeloid leukemia, say authors of a phase II study reported in the Lancet Oncology.

5 Nov 2012

Genetic polymorphisms linked with community-acquired pneumonia

Seven genetic polymorphisms have been shown to be associated with community-acquired pneumonia, research shows.

5 Nov 2012

FDA accepts Sunovion’s two LATUDA sNDAs for review

Sunovion Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review two supplemental New Drug Applications (sNDAs) for the use of LATUDA as 1) monotherapy and 2) adjunctive therapy to lithium or valproate, both to treat adult patients with depressive episodes associated with bipolar I disorder (bipolar depression).

31 Oct 2012

$Most refractory status epilepticus patients have poor functional outcome$

Most refractory status epilepticus patients have poor functional outcome

Three-quarters of refractory status epilepticus patients have a poor functional outcome, which is linked to drug-induced coma and severe encephalographic suppression, say US scientists.

30 Oct 2012

Artificial CSP proteins reduce S. pneumoniae competence y more than 90%

The bacterium Streptococcus pneumoniae - which can cause pneumonia, meningitis, bacteremia and sepsis - likes to share its antibiotic-defeating weaponry with its neighbors. Individual cells can pass resistance genes to one another through a process called horizontal gene transfer, or by "transformation," the uptake of DNA from the environment.

26 Oct 2012

CINJ makes experts available during National Lung Cancer Awareness Month

According to the American Cancer Society, nearly 6,000 new cases of lung cancer are expected to be diagnosed in New Jersey this year, and 4,200 people will die from the disease.

25 Oct 2012

Are some factors related to readmissions beyond hospitals' control?

Reuters reports on a "fresh look at past research" that finds several non-medical variables may be central to how some patients do once they are discharged from the hospital.

22 Oct 2012

MRSA-related pneumonia can be effectively treated in half the recommended time

The national practice guideline for treating MRSA-related pneumonia is seven to 21 days. A Henry Ford Hospital study found that effective treatment can be done in half the time.

20 Oct 2012

Henry Ford study evaluates length of treatment for MRSA-related pneumonia

The national practice guideline for treating MRSA-related pneumonia is seven to 21 days. A Henry Ford Hospital study found that effective treatment can be done in half the time.

20 Oct 2012

Babies born to HIV positive mothers more likely to acquire measles

Non-infected babies born to HIV positive mothers should be vaccinated early against measles, to avoid them acquiring the virus or passing it on to others.

19 Oct 2012

Public-private partnership will promote handwashing to help reduce child mortality in Africa

Though the number of children dying of preventable and treatable diseases worldwide has dropped significantly since 1990, there is "realistic hope for much more" progress, particularly if "improved hygiene and sanitation ... play a key role in the next stage," Jeffrey Sachs, director of the Earth Institute at Columbia University, and Paul Polman, CEO of Unilever, write in the Huffington Post's "Global Motherhood" blog.

17 Oct 2012

NIAID-funded study to evaluate PPSV23 and PCV13 in Phase Iib pneumococcal trial

Researchers plan to see if a higher dose of a pneumococcal vaccine will create a stronger immune response in older adults who received an earlier generation vaccine against pneumonia and other pneumococcal diseases.

16 Oct 2012

Saint Louis University to participate in PPV23 vaccine trial for pneumonia

Saint Louis University is participating in a multi-site, National Institutes of Health-sponsored clinical trial in older adults of a new vaccine designed to protect against one of the most common types of pneumonia and related diseases such as bloodstream infections and meningitis.

16 Oct 2012

Environmental factors affect pneumonia hospitalization in HIV

Hospital admissions for Pneumocystis pneumonia in HIV-infected individuals are significantly more common in the summer months, US research shows.

15 Oct 2012

Celgene receives FDA approval for ABRAXANE to treat non-small cell lung cancer

Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) for the first-line treatment of locally advanced or metastatic non-small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.

15 Oct 2012

Lenalidomide worsens survival, adverse events in prostate cancer

A combination of lenalidomide plus docetaxel and prednisone treatment in patients with chemotherapy-naive prostate cancer leads to worse overall survival rates and increased toxicity compared with placebo, show study results.

12 Oct 2012

Alverix receives FDA 510(k) clearance for new BD Veritor System kit

Alverix, Inc., a world leader in the design and manufacture of next-generation platforms for diagnostic Point-of-Care (POC) testing, today announced that BD Diagnostics, a segment of Becton Dickinson and Company, a leading global medical technology company, received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for nasopharyngeal wash, aspirate and swab in transport media specimens on the BD VeritorTM System for Rapid Detection of respiratory syncytial virus (RSV).

12 Oct 2012

Top-line results from Pfizer’s ALO-02 Phase 3 study on chronic non-cancer pain

Pfizer Inc. announced top-line results today from a Phase 3 open-label long-term safety study of investigational agent ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride extended-release capsules) in patients with moderate-to-severe chronic, non-cancer pain.

12 Oct 2012

Fibulin-3 protein may help identify mesothelioma in early stages

Researchers at NYU School of Medicine have discovered the protein product of a little-known gene may one day prove useful in identifying and monitoring the development of mesothelioma in early stages, when aggressive treatment can have an impact on the progression of disease and patient prognosis.

11 Oct 2012